Justin D. Gover
CIK: 0001754129
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 9, 2026DSGN
Design Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
30K shares- - Jun 3, 2026XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectShare Option (Right to Buy)
10.5K shares- - Jun 3, 2026XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectRestricted Share Units
1.6K shares- - Jun 1, 2026XENE
Xenon Pharmaceuticals Inc.
Exercise(M)Direct2.6K shares- - May 27, 2026CMPS
COMPASS Pathways plc
Award(A)DirectShare Option (Right to Buy)
21.1K shares- - Jan 2, 2026DSGN
Design Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
45K shares- - Sep 9, 2025DSGN
Design Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
15.8K shares- - Sep 9, 2025DSGN
Design Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
30K shares- - Jul 29, 2025CMPS
COMPASS Pathways plc
Award(A)DirectShare Option (Right to Buy)
52K shares- - Jun 5, 2025XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectShare Option (Right to Buy)
17K shares- - Jun 5, 2025XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectRestricted Share Units
2.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 9, 2026 |  DSGN Design Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
| Jun 3, 2026 |  XENE Xenon Pharmaceuticals Inc. | Award(A) Share Option (Right to Buy) | 10,507 | - | - | Direct |
| Jun 3, 2026 | XENE Xenon Pharmaceuticals Inc. | Award(A) Restricted Share Units | 1,593 | - | - | Direct |
| Jun 1, 2026 | XENE Xenon Pharmaceuticals Inc. | Exercise(M) | 2,645 | - | $0 | Direct |
| May 27, 2026 |  CMPS COMPASS Pathways plc | Award(A) Share Option (Right to Buy) | 21,110 | - | - | Direct |
| Jan 2, 2026 | DSGN Design Therapeutics, Inc. | Award(A) Stock option (right to buy) | 45,000 | - | - | Direct |
| Sep 9, 2025 | DSGN Design Therapeutics, Inc. | Award(A) Stock option (right to buy) | 15,833 | - | - | Direct |
| Sep 9, 2025 | DSGN Design Therapeutics, Inc. | Award(A) Stock option (right to buy) | 30,000 | - | - | Direct |
| Jul 29, 2025 | CMPS COMPASS Pathways plc | Award(A) Share Option (Right to Buy) | 52,000 | - | - | Direct |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | Award(A) Share Option (Right to Buy) | 17,012 | - | - | Direct |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | Award(A) Restricted Share Units | 2,645 | - | - | Direct |
1-11 of 11 transactions
About Gover Justin D.
Gover Justin D. (SEC CIK 0001754129) files insider reports with the SEC as Director of Design Therapeutics, Inc. (DSGN), Director of Xenon Pharmaceuticals Inc. (XENE) and Director of COMPASS Pathways plc (CMPS).
Signal8 holds 9 ownership filings by Gover Justin D. (2 Form 3, 7 Form 4), filed between Jun 6, 2025 and Jun 11, 2026. Those filings report 11 transactions, from Jun 5, 2025 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Gover Justin D.'s filings is in BURNABY.
Recent filings by Gover Justin D.
- Jun 9, 2026: Grant or award of DSGN derivative securities (Form 4, code A).
- Jun 3, 2026: Grants or awards of XENE derivative securities (2 lines, Form 4, code A).
- Jun 1, 2026: Option exercise of XENE shares (Form 4, code M).
- May 27, 2026: Grant or award of CMPS derivative securities (Form 4, code A).
- Jan 2, 2026: Grant or award of DSGN derivative securities (Form 4, code A).
Other insiders filing for Design Therapeutics, Inc. (DSGN)
- George Simeon, Director
- Schmid John P., Director
- LAPPE RODNEY W, Director
- Shapiro David, Director
- Berger Heather A., Director
- Storgard Chris, Chief Medical Officer